Quantcast

Industry news that matters to you.  Learn more

Archives for March 2011

MedTrust Online, Avantra Biosciences Collaborate to Involve Clinicians in Assay Development

MedTrust Online and Avantra Biosciences recently announced that they will collaborate on involving clinicians in early-stage development of molecular diagnostic assays to run on Avantra Biosciences’ QPDx multiplex immunoassay system.

Biomarker May Prove Useful for Diagnosing Knee Injury

Researchers from Stanford University School of Medicine recently discovered a biomarker that may enable doctors to diagnose a common form of knee injury. The study, published in the Journal of Bone and Joint Surgery, has identified a specific protein complex in the knee fluid of patients with painful meniscal tears.

Glycated Albumin Presented as a Novel Biomarker for Diabetes Monitoring

The American Association for Clinical Chemistry (AACC) presented a webinar on February 24th, 2011, titled “Novel Biomarkers for the Diagnosis and Management of Diabetes,” in which glycated albumin (GA) was described as a promising biomarker for patients who are underserved by usual diabetes monitoring methods. Glycated albumin is the cornerstone of Epinex’s flagship product — the G1A™ Rapid Diabetes Monitoring Index Test.

OncoTrack Launches Search for Novel Genomic Cancer Diagnostics

A new European consortium called OncoTrack has just launched one of Europe’s largest collaborative academic-industry research projects to develop and assess novel approaches for the identification of new biomarkers for colon cancer. The five year project, Methods for systematic next generation oncology biomarker development, brings together top European academic researchers with a wide range of expertise and partners them with pharmaceutical companies.

Aushon BioSystems and Peking University Cancer Hospital Collaborate on Predictive Diagnostic Biomarkers for Liver Metastases of Colorectal Cancer

Aushon BioSystems, Inc., recently announced that it has signed a letter of intent to enter into a diagnostic development collaboration with Peking University Cancer Hospital, Beijing, China. The primary goal for the collaboration is to develop predictive diagnostic markers for liver metastases of colorectal cancer utilizing Aushon’s proprietary suite of protein biomarker detection technologies, and stratification biomarkers for radio-chemotherapy patients. As part of this collaboration, Peking University Cancer Hospital and Aushon will further negotiate an agreement to grant Aushon exclusive rights In North America and Europe to certain intellectual property generated from the collaboration for diagnostic applications.